Terns Net Receivables vs Net Tangible Assets Analysis
TERN Stock | USD 5.90 0.24 3.91% |
Terns Pharmaceuticals financial indicator trend analysis is much more than just breaking down Terns Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Terns Pharmaceuticals is a good investment. Please check the relationship between Terns Pharmaceuticals Net Receivables and its Net Tangible Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
Net Receivables vs Net Tangible Assets
Net Receivables vs Net Tangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Terns Pharmaceuticals Net Receivables account and Net Tangible Assets. At this time, the significance of the direction appears to have pay attention.
The correlation between Terns Pharmaceuticals' Net Receivables and Net Tangible Assets is -0.72. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Terns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Terns Pharmaceuticals' Net Receivables and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Terns Pharmaceuticals are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Net Receivables i.e., Terns Pharmaceuticals' Net Receivables and Net Tangible Assets go up and down completely randomly.
Correlation Coefficient | -0.72 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Net Receivables
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most indicators from Terns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 19th of May 2024, Selling General Administrative is likely to grow to about 41 M, while Issuance Of Capital Stock is likely to drop about 39.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 170K | 2.1M | 12.9M | 13.5M | Net Interest Income | 170K | 2.1M | 12.9M | 13.5M |
Terns Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Terns Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Terns Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.9M | 92.3M | 168.1M | 287.0M | 268.5M | 170.3M | |
Other Current Liab | 3.3M | 8.2M | 4.7M | 6.2M | 7.6M | 5.8M | |
Total Current Liabilities | 5.0M | 22.8M | 6.8M | 8.5M | 11.9M | 10.5M | |
Total Stockholder Equity | 4.2M | 68.6M | 160.3M | 276.9M | 255.4M | 153.6M | |
Other Liab | 630K | 877K | 947K | 1.1M | 1.2M | 806.7K | |
Net Tangible Assets | (90.8M) | (117.4M) | 172.2M | 276.9M | 318.5M | 334.4M | |
Property Plant And Equipment Net | 961K | 1.2M | 1.0M | 1.8M | 1.0M | 1.2M | |
Net Debt | (12.3M) | (62.0M) | (47.7M) | (142.0M) | (79.3M) | (83.3M) | |
Retained Earnings | (91.9M) | (131.9M) | (182.1M) | (242.4M) | (332.6M) | (316.0M) | |
Accounts Payable | 1.6M | 935K | 2.1M | 1.6M | 2.5M | 1.8M | |
Cash | 12.3M | 74.9M | 47.7M | 143.2M | 79.9M | 80.8M | |
Non Current Assets Total | 1.7M | 1.4M | 1.1M | 1.8M | 1.1M | 1.4M | |
Non Currrent Assets Other | 719K | 246K | 94K | 37K | 56K | 53.2K | |
Other Assets | 719K | 246K | 94K | 37K | 1.0 | 0.95 | |
Cash And Short Term Investments | 19.7M | 74.9M | 166.0M | 283.1M | 263.4M | 163.9M | |
Common Stock Shares Outstanding | 25.1M | 25.1M | 25.3M | 36.0M | 71.3M | 37.9M | |
Short Term Investments | 7.3M | 0.0 | 118.3M | 139.9M | 183.5M | 192.7M | |
Liabilities And Stockholders Equity | 23.9M | 92.3M | 168.1M | 287.0M | 268.5M | 170.3M | |
Non Current Liabilities Total | 14.7M | 877K | 947K | 1.6M | 1.2M | 1.1M | |
Other Current Assets | 461K | 331K | 948K | 2.1M | 4.0M | 4.2M | |
Other Stockholder Equity | 1.2M | 14.6M | 174.6M | 520.2M | 588.0M | 617.4M | |
Total Liab | 19.7M | 23.7M | 7.8M | 10.1M | 13.2M | 12.2M | |
Net Invested Capital | (90.8M) | (104.6M) | 160.3M | 276.9M | 255.4M | 268.1M | |
Property Plant And Equipment Gross | 961K | 1.2M | 2.2M | 3.2M | 2.6M | 1.9M | |
Total Current Assets | 22.2M | 90.9M | 166.9M | 285.2M | 267.4M | 168.9M | |
Accumulated Other Comprehensive Income | (106K) | (124K) | (338K) | (822K) | (19K) | (20.0K) | |
Net Working Capital | 17.3M | 68.0M | 160.1M | 276.7M | 255.5M | 158.4M | |
Property Plant Equipment | 961K | 1.2M | 1.0M | 757K | 870.6K | 924K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Terns Stock analysis
When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 0.035 | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.